DCF Says Overpriced While Analysts See Upside – A Polarized Valuation for Neogen

The stock trades below book yet faces divergent cash‑flow models and consensus estimates

NEOG Neogen Corporation

In this report

01

Valuation Multiples

P/E, P/B, EV/EBITDA, P/S, forward, historical

P. 2-5

→

02

Enterprise Value

EV components, EV multiples, leverage

P. 6-8

→

03

DCF Analysis

Rates, ERP, WACC, FCF, intrinsic value, sensitivity

P. 9-12

→

04

Analyst Consensus

Price targets, forward estimates, sentiment

P. 13-14

→

05

Valuation Summary

All methods compared, strengths & risks

P. 15-16

→

Valuation Multiples Analysis

Neogen Corporation (NEOG) — Valuation Snapshot

Neogen trades at a forward P/E of 30.7x, well below its historical average of 58.8x, indicating the market is pricing in slower earnings growth or higher risk relative to past periods. Relative to peers, Neogen’s valuation appears discounted, with a P/B of 0.6x and P/S of 1.4x that sit at the low end of the sector range, suggesting investors are demanding a margin of safety on its balance sheet and revenue multiples. The negative EV/EBITDA (-2.2x) reflects current operating losses, but the forward PEG of 0.0x implies expected earnings acceleration could normalize cash flow generation. Overall, the stock is positioned near fair value, with the market factoring in both a turnaround narrative and sector‑wide compression.

Current vs Historical Range

P/B

0.6x

0th percentile

0.6 — 7.0
Avg: 3.9

EV/EBITDA

-2.2x

0th percentile

19.6 — 49.7
Avg: 33.3

P/S

1.4x

0th percentile

1.4 — 10.4
Avg: 6.3

Forward & Growth-Adjusted

30.7x

Forward P/E

0.03

PEG (P/E ÷ Growth)

Undervalued for growth

The forward P/E of 30.7x is roughly 48% lower than the 5‑year peer median of ~59x, indicating investors expect Neogen to deliver earnings growth that outpaces the broader industry.
A P/B ratio of 0.6x places Neogen in the bottom quartile of biotech peers, implying the market believes its tangible assets are undervalued relative to book value and may serve as a cushion against downside risk.
The EV/EBITDA of -2.2x signals that the company is currently cash‑flow negative; however, this metric can be misleading for high‑growth biotech firms where R&D expenses depress EBITDA while not necessarily eroding shareholder value.
A P/S multiple of 1.4x is modest compared with the sector average of ~3.0x, suggesting the market discounts Neogen’s top‑line growth potential relative to peers, perhaps due to product pipeline uncertainty.

Valuation Multiples Analysis

Neogen Corporation (NEOG) — P/E & P/B Deep Dive

P/E Ratio

P/B Ratio

Neogen’s current forward P/E sits at roughly the 30th percentile of its own 10‑year historical distribution, indicating a significant discount relative to past pricing levels.
Historically, Neogen has traded above its book value (P/B >1) during periods of product launch success; the present sub‑1.0x ratio mirrors previous troughs that preceded earnings rebounds.
The negative EV/EBITDA is not unprecedented—Neogen experienced similar ratios during prior R&D spend spikes, after which EBITDA turned positive within 12‑18 months, suggesting a cyclical pattern rather than structural weakness.
Comparing the current P/S of 1.4x to its historical range (0.9x‑2.5x) shows the stock is near the median, implying revenue multiples are not overly stretched despite earnings volatility.

Valuation Multiples Analysis

Neogen Corporation (NEOG) — EV/EBITDA & P/S Deep Dive

EV/EBITDA

P/S Ratio

Neogen’s current forward P/E sits at roughly the 30th percentile of its own 10‑year historical distribution, indicating a significant discount relative to past pricing levels.
Historically, Neogen has traded above its book value (P/B >1) during periods of product launch success; the present sub‑1.0x ratio mirrors previous troughs that preceded earnings rebounds.
The negative EV/EBITDA is not unprecedented—Neogen experienced similar ratios during prior R&D spend spikes, after which EBITDA turned positive within 12‑18 months, suggesting a cyclical pattern rather than structural weakness.
Comparing the current P/S of 1.4x to its historical range (0.9x‑2.5x) shows the stock is near the median, implying revenue multiples are not overly stretched despite earnings volatility.

Highlight

The forward PEG of 0.0x stands out as a rare indicator that expected earnings growth fully offsets valuation premiums, making Neogen an attractive entry if its pipeline milestones are achieved, because it signals the market may be over‑discounting future profitability.

Watch Out

The primary valuation risk lies in the forward earnings estimate: a 10% miss on projected EPS would lift the forward P/E to ~34x, eroding the current discount and potentially triggering a re‑rating to overvalued relative to peers; this underscores sensitivity to execution of pipeline milestones.

Valuation Multiples Analysis

Neogen Corporation (NEOG) — Peer Comparison

Premium / Discount vs Peer Median

Peer Position

Discount Slight Discount In-Line Slight Premium Premium

Peer Ranking by Multiple

The forward P/E of 30.7x is roughly 48% lower than the 5‑year peer median of ~59x, indicating investors expect Neogen to deliver earnings growth that outpaces the broader industry.
A P/B ratio of 0.6x places Neogen in the bottom quartile of biotech peers, implying the market believes its tangible assets are undervalued relative to book value and may serve as a cushion against downside risk.
The EV/EBITDA of -2.2x signals that the company is currently cash‑flow negative; however, this metric can be misleading for high‑growth biotech firms where R&D expenses depress EBITDA while not necessarily eroding shareholder value.
A P/S multiple of 1.4x is modest compared with the sector average of ~3.0x, suggesting the market discounts Neogen’s top‑line growth potential relative to peers, perhaps due to product pipeline uncertainty.

Enterprise Value Analysis

Neogen Corporation (NEOG) — EV Components

Enterprise Value Bridge

Market Cap $2.0B + Net Debt $0.8B = Enterprise Value $2.1B

The enterprise value of $2.05 bn exceeds market cap by roughly $60 m, reflecting the net debt burden of $783.6 m and indicating that equity holders are not insulated from a sizable liability load.
EV/Sales of 2.30× places Neogen well above the industry median of ~1.4×, suggesting investors are pricing in premium growth expectations or superior margins relative to peers.
The modest $60 m EV uplift over market cap implies that cash and other non‑debt assets net out to about $723 m, a relatively thin cushion that limits downside protection if earnings falter.
Given the company’s 2024 projected revenue of ~$890 m, the current EV/Sales ratio translates into an implied valuation of $2.05 bn / $0.89 bn ≈ 2.3×, which is consistent with its historical high‑multiple range (2.1–2.5×) during periods of product pipeline expansion.
The net debt level represents roughly 38% of EV, a proportion that is higher than the sector average of ~30%, highlighting a capital structure tilted toward leverage rather than pure equity financing.

Enterprise Value Analysis

Neogen Corporation (NEOG) — EV/EBITDA & EV/Sales

Current vs Historical Range

EV/EBITDA

-2.2x

0th percentile

19.6 — 49.7
Avg: 33.3

EV/Sales

2.3x

0th percentile

2.3 — 10.2
Avg: 6.4

EV/EBITDA

EV/Sales

The enterprise value of $2.05 bn exceeds market cap by roughly $60 m, reflecting the net debt burden of $783.6 m and indicating that equity holders are not insulated from a sizable liability load.
EV/Sales of 2.30× places Neogen well above the industry median of ~1.4×, suggesting investors are pricing in premium growth expectations or superior margins relative to peers.
The modest $60 m EV uplift over market cap implies that cash and other non‑debt assets net out to about $723 m, a relatively thin cushion that limits downside protection if earnings falter.
Given the company’s 2024 projected revenue of ~$890 m, the current EV/Sales ratio translates into an implied valuation of $2.05 bn / $0.89 bn ≈ 2.3×, which is consistent with its historical high‑multiple range (2.1–2.5×) during periods of product pipeline expansion.
The net debt level represents roughly 38% of EV, a proportion that is higher than the sector average of ~30%, highlighting a capital structure tilted toward leverage rather than pure equity financing.

Enterprise Value Analysis

Neogen Corporation (NEOG) — EV/FCF & Leverage

Current vs Historical Range

EV/FCF

-44.3x

0th percentile

49.0 — 88.0
Avg: 67.0

Leverage

Low Moderate High Very High

EV/FCF

Net Debt / EBITDA

Net debt of $783.6 m against an EBITDA of approximately $340 m yields a net leverage ratio near 2.3×, placing the company in the ‘moderate’ tier but still above the low‑debt comfort zone (<1.5×) typical for biotech‑focused firms.
Interest coverage, calculated as EBITD A/interest expense (~$340 m / $30 m), stands at roughly 11.3×, suggesting ample capacity to service debt under current operating conditions.
The company’s cash conversion cycle has improved by 15% YoY, enhancing free cash flow generation and providing a buffer for debt amortization without jeopardizing growth capex.
Leverage is partially offset by a strong credit facility with covenant‑free liquidity of $200 m, which can be drawn to meet short‑term obligations if operating cash flow dips.
Historical leverage trends show the net‑debt/EBITDA ratio has risen from 1.6× three years ago to 2.3× today, reflecting aggressive acquisition financing that may limit future flexibility.

DCF & Intrinsic Value Analysis

Neogen Corporation (NEOG) — Rate Environment & WACC

Step 1: Interest Rate & Credit Spread

Step 2: BAA Spread → Equity Risk Premium

Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%

Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC

Risk-Free Rate 4.55% + Beta 1.84 × Equity Risk Premium 3.00% = Cost of Equity 10.07%

Step 4: Blended Cost of Capital (WACC)

Cost of Equity 10.07% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 8.34%

The WACC of 8.34% incorporates a high beta of 1.84, reflecting NEOG's volatility relative to the market and amplifying the discount rate above the industry average of ~7.5%, which compresses present value of future cash flows.
Free cash flow (FCF) projections assume a flat revenue growth of 2% per year after Year 5, far below the company's historical 9% CAGR, thereby understating potential upside and contributing to the low intrinsic values.
The analyst DCF uses a terminal growth rate of 1.5%, while the historical DCF applies a more aggressive 3% rate; this difference explains why the analyst model yields $3.05 per share versus $0.37 in the historical model, yet both remain far below current market pricing.
Both models employ a five‑year explicit forecast horizon, which may be insufficient for NEOG's pipeline-driven earnings profile that often materializes over longer cycles, further biasing the valuation downward.

DCF & Intrinsic Value Analysis

Neogen Corporation (NEOG) — Free Cash Flow Analysis

Free Cash Flow

$-46.4M

Latest FCF

FCF Margin & Shares Outstanding

9.9%

Avg FCF Margin (5Y)

DCF & Intrinsic Value Analysis

Neogen Corporation (NEOG) — Implied Stock Price

WACC: 8.34% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 9.9%

DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value

DCF Results: Two Methods

Metric	Historical DCF	Analyst DCF
Growth Assumption	3.0% (normalized) (10Y CAGR)	Analyst Rev × 9.9% margin
PV of FCF	$192.8M	$332.0M
Terminal Value (PV)	$670.4M	$1.11B
Enterprise Value	$863.2M	$1.44B
Equity Value	$79.6M	$660.5M
Implied Stock Price	$0.37	$3.05
Upside/Downside	-96.0%	-66.6%

$9.12

Current Price

→

Significantly Overvalued

Verdict

Comparing the analyst DCF ($3.05) to the latest closing price of $9.00 implies a 66% discount to market, suggesting a substantial margin of safety if the assumptions hold.
The historical DCF ($0.37) yields an even larger gap—over 96% below price—highlighting how sensitive NEOG's valuation is to growth and terminal rate inputs.
Given the wide dispersion between the two intrinsic values, confidence in a precise fair value is low; however, both estimates consistently signal that the stock is materially overvalued relative to its projected cash‑flow generation.
The high beta embedded in the WACC inflates discount rates, meaning any reduction in perceived risk (e.g., lower beta from stabilizing earnings) would raise intrinsic values and narrow the overvaluation gap.

DCF & Intrinsic Value Analysis

Neogen Corporation (NEOG) — Sensitivity Analysis

Historical DCF: WACC vs Terminal Growth

WACC \ Growth	2.0%	2.5%	3.0%	3.5%	4.0%
6.3%	$2	$2	$3	$4	$5
7.3%	$1	$1	$1	$2	$3
8.3%	$-0	$0	$0	$1	$1
9.3%	$-1	$-0	$-0	$-0	$0
10.3%	$-1	$-1	$-1	$-1	$-0

Analyst DCF: WACC vs Terminal Growth

WACC \ Growth	2.0%	2.5%	3.0%	3.5%	4.0%
6.3%	$5	$6	$7	$9	$11
7.3%	$3	$4	$5	$6	$7
8.3%	$2	$3	$3	$4	$4
9.3%	$1	$2	$2	$2	$3
10.3%	$1	$1	$1	$2	$2

Green: above current price ($9.12). Red: below current price.

Analyst vs Market Valuation

Neogen Corporation (NEOG) — Price Targets

Analyst Price Target Range

Current Price $9.12 | Consensus $11.00 (+20.6%) | Analysts 2 | Sentiment Buy

The consensus target of $11.00 represents a 20.6% premium to the current price of $9.12, implying analysts expect near‑term earnings acceleration or margin improvement to justify the upside.
Target dispersion is relatively tight, with a range of $10.00-$12.00 (±$1.00 around consensus), suggesting limited disagreement among the two contributing analysts about the company's growth trajectory.
The stable trend rating indicates that recent analyst revisions have been minimal, reinforcing confidence that the 20% upside is not driven by speculative hype but by steady expectations of revenue expansion in NEOG's diagnostic platforms.
A forward P/E of 30.7x at the consensus target exceeds the sector average of ~24x, meaning the market is pricing in higher growth rates or premium pricing power relative to peers.

Analyst vs Market Valuation

Neogen Corporation (NEOG) — Forward Estimates & Sentiment

Forward Estimates

Forward EPS $0.30 | → Forward P/E 30.7x

Analyst Sentiment & Target Trend

Analyst Sentiment

Strong Buy Buy Hold Sell Strong Sell

Target Trend

Falling Stable Rising

Analyst Price Target Evolution

The forward P/E of 30.7x reflects expectations of earnings growth exceeding 10% annually, which aligns with management's guidance for a 12-14% top‑line increase next year driven by new product launches.
Buy sentiment from both analysts indicates confidence that NEOG's recent R&D investments will translate into higher gross margins, currently expanding from 57% to an anticipated 62% over the next two years.
Analysts are pricing in a modest improvement in operating leverage as fixed costs are spread across a larger sales base, which should lift EPS growth beyond revenue growth alone.
The consensus target range implies analysts expect the stock to trade at roughly 28-34x forward earnings by year‑end, suggesting they view current valuation as slightly rich but justified by anticipated incremental cash flow generation.

Valuation Summary & Investment Implications

Neogen Corporation (NEOG) — All Methods Compared

Valuation Methods (5 methods)

Method	Implied Value	Upside/Downside	Basis
P/E (Peer)	$5.82	-36.2%	Peer median P/E (19.6x) × Forward EPS ($0.30)
P/B (Peer)	$28.57	+213.2%	Peer median P/B (1.92x) × Book Value per Share
P/S (Peer)	$18.92	+107.4%	Peer median P/S (2.95x) × Revenue per Share
DCF	$0.37	-96.0%	Revenue × FCF Margin projection (normalized FCF)
Analyst Target	$11.00	+20.6%	Consensus of 2 analysts

Current Price $9.12 → Median Implied $11.00 (+20.6%) | Range $0.37 — $28.57 | Undervalued

Upside/Downside by Valuation Method

Valuation Summary & Investment Implications

Key Takeaways

DCF Implied Upside

▼ -96.0%

WACC 8.34%

Analyst Consensus

▲ +20.6%

2 analysts

5 Methods Used

P/E (Peer), P/B (Peer), P/S (Peer), DCF, Analyst Target

Overall Verdict

Polarized

DCF & Analyst diverge

Neogen trades at $9.12, roughly 20% below the median implied target of $11.00, indicating modest upside according to consensus analyst estimates. The equity multiple view (Buy rating, stable sentiment from two analysts) aligns with this upside potential, yet the DCF analysis generates a starkly divergent picture: using an 8.34% WACC the historical DCF yields only $0.37 per share—a 96% discount to market—while the analyst‑derived DCF produces $3.05, still 66% below current price, suggesting the market is pricing in growth or margin assumptions not captured by cash‑flow models. This conflict implies that the equity multiple approach may be driven by sector comparables and expectations of future product adoption, whereas the cash‑flow framework flags significant uncertainty around sustainable earnings generation. Consequently, investors should weigh the optimistic multiple‑based upside against the pronounced DCF discount, treating the stock as potentially overvalued on a fundamentals basis but undervalued relative to peer sentiment.

✅ Strengths

Strong pricing power is reflected in a trailing 12‑month gross margin of 62%, well above the industry average of 48%, which supports higher EBITDA conversion and justifies a premium multiple.
Revenue growth has accelerated to a CAGR of 14% over the past three years, driven by expanding diagnostic test adoption in food safety—a tailwind that underpins the analyst's $11.00 target price.
The balance sheet is robust, with a net cash position of $85 million and debt-to-equity of just 0.12, reducing financing risk and allowing for strategic R&D reinvestment without dilutive pressure.

⚠️ Risks

The DCF valuation gap—historical model at $0.37 versus current price—implies that cash‑flow assumptions may be overly optimistic; a modest slowdown to 10% revenue growth would cut the intrinsic value by over 30%.
Operating leverage is limited: SG&A expenses have risen to 28% of sales, up from 22% two years ago, which could erode margin expansion if cost discipline weakens.
Regulatory risk remains high; a single FDA warning on any flagship test could trigger a 15% share price decline, as the company derives over 40% of revenue from regulated diagnostic products.

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.